TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bacterial envelope with ICD replacements

News | 03. 24. 2010

TYRX

 

MONMOUTH JUNCTION, N.J., March 24, 2010–(EON: Enhanced Online News) – TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce infection, announced today that it has begun enrollment in CITADEL, the second of two large scale, prospective, multicenter studies.